It’s a battle of two heavyweights in this trial report from the Journal of Clinical Oncology, sharing the results of acalabrutinib (Calquence) compared to ibrutinib (Imbruvica) in treating chronic lymphocytic leukemia (CLL). Selected events of clinical interest included cardiac events, atrial fibrillation, ventricular tachyarrhythmias, hypertension, bleeding and major bleeding events, infections, and second primary malignancies […]
In this interview with Dr. Richard Furman, Professor of Medicine at New York-Presbyterian Weill Cornell Medicine, the importance of the CLL14 study is highlighted. In addition, Dr. Furman discusses the best use of venetoclax and whether anti-CD20 agents really add to the benefit of venetoclax treatment and whether a policy of watch and wait is […]
This Research Article from Blood – available as a PDF – discusses two main points. First, antibody response to BNT162b2 mRNA COVID19 vaccine in CLL patients is markedly impaired and affected by disease activity and treatment. The second point shows that, in patients treated with either Bruton’s tyrosine kinase inhibitors (TKIs) or venetoclax ± anti-CD20 […]
Warm autoimmune hemolytic anemia (wAIHA) is the most prevalent form of autoimmune hemolytic anemia (AIHA), accounting for 60% to 70% of all cases. In this special instructional series from Blood (ASH), five patient case studies and commentaries are examined, backed by visual illustrations and new/existing drug treatment tables for wAIHA, wAIHA secondary to CLL, and […]
For the estimated 21,000 patients who will receive a diagnosis of chronic lymphocytic leukemia (CLL), 20% of them will have early-stage disease. Unfortunately, that 20% will not be offered treatment, as the current management of these patients follows a “watch-and-wait” paradigm. However, with the advent of better prognostic tools to identify patients at high risk, […]
This article presents a review and commentary of selected presentations from the all-virtual 62nd American Society of Hematology (ASH) Meeting and Exposition, which took place in December 2020. Coverage includes safety and efficacy results in trials of acalabrutinib, venetoclax, obinutuzumab, rituximab, LOXO-305, idelalisib, bendamustine, umbralisib, ublituximab, chlorambucil, lisocabtagene maraleucel, and others.
From the pages of Clinical Advances in Hematology & Oncology comes this Q&A with Jennifer A. Woyach, MD, a Professor of Medicine in the Division of Hematology at the Ohio State University Comprehensive Cancer Center. Dr. Woyach provides extensive commentary on BTK, BCL2, and PI3K inhibitors, FCR usage, and the importance of clinical trials when […]
Are traditional cytotoxic chemotherapies becoming a thing of the past? This study in the Journal of Clinical Oncology shows a move toward targeted agents, as a combination of obinutuzumab, ibrutinib, and venetoclax induced deep remissions in patients with treatment-naive or relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).